Earlier this year, @UCL spinout company Autolus Therapeutics announced that the U.S. Food and Drug Administration (FDA) had granted marketing approval for AUCATZYL® (obecabtagene autoleucel, obe-cel), for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). UCLB has supported Autolus in protecting and licensing the obe-cel technology, enabling it to attract further capital to fund its development. More here: https://t.co/ZXqNNcT9e4 #BioPharm# #TechTransfer# #Spinouts#

The @FinancialTimes has run a piece highlighting UCLB spinout Autolus Therapeutics’ journey to produce therapies for cancer side effects 👏 The news story focuses on the work taking place at Autolus’ Stevenage facility, which is manufacturing the latest generation of an innovative, personalised cancer treatment: a new Car-T cell therapy to treat the blood cancer acute lymphoblastic leukaemia. 📖 Read more here: https://t.co/3IBqRtuZsL